SCHEMBL2550783

SCHEMBL2550783

CN(C)[C@H]1CCN(c2nc(-n3cccn3)nc(N)c2Br)C1.COC[C@H]1CCCN1c1nc(-n2cccn2)nc(N)c1Br

nearest known ligand 0.79

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 17/20 0.79
ADORA3 P0DMS8 1/20 0.43
ADORA2B P29275 1/20 0.43
ADORA1 P30542 1/20 0.43
PDE10A Q9Y233 1/20 0.36
NMT1 P30419 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2550785 1.00 ADORA2A (0.79) ADORA2AADORA3ADORA2BADORA1PDE10A
SCHEMBL2555841 0.89 ADORA2A (1.00) ADORA2AADORA3ADORA2BADORA1PDE10A
SCHEMBL2555844 0.89 ADORA2A (1.00) ADORA2AADORA3ADORA2BADORA1PDE10A
SCHEMBL2557074 0.86 ADORA2A (0.63) ADORA2AADORA3ADORA2BADORA1PDE10A
SCHEMBL2557077 0.86 ADORA2A (0.63) ADORA2AADORA3ADORA2BADORA1PDE10A
SCHEMBL2554298 0.78 ADORA2A (0.65) ADORA2AADORA3ADORA2BADORA1PDE10A
SCHEMBL2554296 0.78 ADORA2A (0.65) ADORA2AADORA3ADORA2BADORA1PDE10A
SCHEMBL27904499 0.76 ADORA2A (0.76) ADORA2AADORA3ADORA2BADORA1PDE10A
SCHEMBL27887643 0.76 ADORA2A (0.76) ADORA2AADORA3ADORA2BADORA1PDE10A
SCHEMBL2555106 0.76 ADORA2A (0.76) ADORA2AADORA3ADORA2BADORA1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2552909-A1 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS Palobiofarma, S.L. (ES) 2013-02-06 EP disclosed
WO-2011121418-A1 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS PALOBIOFARMA, S.L. (ES) 2011-10-06 WO disclosed